Otsuka Corporation (OSUKF)
| Market Cap | 7.06B -10.7% |
| Revenue (ttm) | 8.50B +16.9% |
| Net Income | 418.23M +18.1% |
| EPS | 1.10 +17.7% |
| Shares Out | n/a |
| PE Ratio | 16.87 |
| Forward PE | n/a |
| Dividend | 0.61 (3.19%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 1,000 |
| Average Volume | 580 |
| Open | 21.57 |
| Previous Close | 20.77 |
| Day's Range | 19.00 - 21.57 |
| 52-Week Range | 19.00 - 23.04 |
| Beta | 0.30 |
| RSI | n/a |
| Earnings Date | Apr 30, 2026 |
About Otsuka
Otsuka Corporation, together with its subsidiaries, provides information services in Japan. It operates through System Integration Business, and Service and Support Business segments. The System Integration Business segment offers computers, copiers, and communication equipment and software, as well as consigned software development and other activities. This segment also provides system services, such as consulting, system design and development, transport and installation work, and network construction services. The Service and Support Busine... [Read more]
Financial Performance
In 2025, Otsuka's revenue was 1.32 trillion, an increase of 19.42% compared to the previous year's 1.11 trillion. Earnings were 64.30 billion, an increase of 20.24%.
Financial numbers in JPY Financial StatementsNews
Esperion announces Otsuka submitted NDA to Japanese MHLW for bempedoic acid
Esperion (ESPR) announced that Otsuka Pharmaceutical (OSUKF) has submitted a New Drug Application, NDA, to the Japanese Ministry of Health, Labour and Welfare, MHLW, for the manufacture and sale of
Otsuka Corp. upgraded to Buy from Neutral at Citi
Citi analyst Mitsunobu Tsuruo upgraded Otsuka Corp. to Buy from Neutral with a price target of 7,200 yen, up from 6,000 yen. The analyst sees sustained earnings growth for the